AI Article Synopsis
Article Abstract
The action of cremophor EL, the solubilizing agent of Althesin in a case of anaphylactic reaction which occurred during the induction of anaesthesia has been demonstrated using the Prausnitz-Küstner (P-K) test 10 weeks later. This test was positive at 2 h, with the heated serum and cremophor, proving the presence of allergic IgG STS antibodies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/bja/55.5.469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT).
Front Immunol
July 2024
Institute of Regional Health Research and, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Article Synopsis
- This study investigates how comorbidities, especially vascular ones, affect patients with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and MOG-antibody-associated disease (MOGAD), potentially worsening their neurological condition.* -
- The proposed study, called COMMIT, will involve a diverse group of patients and will analyze various biological markers related to inflammation and neurodegeneration using advanced technologies and data analysis methods.* -
- The ultimate aim is to understand the influence of comorbidities on the clinical outcomes of these CNS diseases, potentially leading to better treatment strategies for improving patient health and quality of life.*
Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus.
J Biomed Sci
May 2024
Heidelberg ImmunoTherapeutics GmbH, Max-Jarecki Str. 21, Heidelberg, 69115, Germany.
Background: Infections with Herpes simplex virus (HSV)-1 or -2 usually present as mild chronic recurrent disease, however in rare cases can result in life-threatening conditions with a large spectrum of pathology. Monoclonal antibody therapy has great potential especially to treat infections with virus resistant to standard therapies. HDIT101, a humanized IgG targeting HSV-1/2 gB was previously investigated in phase 2 clinical trials.
View Article and Find Full Text PDFDistinctive Adsorption Mechanism and Kinetics of Immunoglobulin G on a Nanoscale Polymer Surface.
Langmuir
February 2022
Department of Chemistry, Georgetown University, 37th & O Sts. NW., Washington, D.C. 20057, United States.
Elucidation of protein adsorption beyond simple polymer surfaces to those presenting greater chemical complexity and nanoscopic features is critical to developing well-controlled nanobiomaterials and nanobiosensors. In this study, we repeatedly and faithfully track individual proteins on the same nanodomain areas of a block copolymer (BCP) surface and monitor the adsorption and assembly behavior of a model protein, immunoglobulin G (IgG), over time into a tight surface-packed structure. With discrete protein adsorption events unambiguously visualized at the biomolecular level, the detailed assembly and packing states of IgG on the BCP nanodomain surface are subsequently correlated to various regimes of IgG adsorption kinetic plots.
View Article and Find Full Text PDFThe role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
J Control Release
February 2022
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St., Glasgow G4 0RE, Scotland, UK. Electronic address:
The efficacy of RNA-based vaccines has been recently demonstrated, leading to the use of mRNA-based COVID-19 vaccines. The application of self-amplifying mRNA within these formulations may offer further enhancement to these vaccines, as self-amplifying mRNA replicons enable longer expression kinetics and more potent immune responses compared to non-amplifying mRNAs. To investigate the impact of administration route on RNA-vaccine potency, we investigated the immunogenicity of a self-amplifying mRNA encoding the rabies virus glycoprotein encapsulated in different nanoparticle platforms (solid lipid nanoparticles (SLNs), polymeric nanoparticles (PNPs) and lipid nanoparticles (LNPs)).
View Article and Find Full Text PDFA phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Vaccine
January 2022
Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address:
Background: Pneumococcal conjugate vaccines (PCVs) have greatly reduced the incidence of pneumococcal disease, yet unmet medical need remains due to increased disease caused by non-vaccine serotypes (STs). V114 (VAXNEUVANCE, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!